LetiFend®: vaccine against canine leishmaniasis
Safety
Excellent tolerability shown in a wide range of breeds and ages.
Efficacy
72% prevention of canine leishmaniasis in areas at high risk of infection by Leishmania infantum.
Convenience
A single annual dose confers immunity for 365 days.
Speed
Protection against development of the disease from 28 days after vaccination.
Reliability
Specific immune response to vaccination that does not interfere with the serological diagnosis of the disease.
Efficacy confirmed in laboratory studies
Different laboratory studies conducted with experimental infection with Leishmania infantum showed that LetiFend®:
- Reduces development of the disease.
- Reduces clinical signs.
- Reduces parasite load in the spleen and lymph glands.
- Protects from 28 days.
- Duration of immunity: 1 year.
LetiFend® reduces the risk of developing clinical leishmaniasis
A dog vaccinated with LetiFend® presents:
Vaccination with LetiFend® does not interfere with the diagnosis of leishmaniasis
LetiFend®, a DIVA (Differentiating Infected from Vaccinated Animals) vaccine which allows discrimination between vaccinated and infected animals.
- Serums of animals vaccinated with LetiFend® were subject to the serological tests most widely used for the diagnosis of Leishmaniasis (ELISA, IIF and snap tests).
- The results showed that none of the evaluated tests were positive after analysis of the serums.
LetiFend® enables the vaccination of a population of animals susceptible to catching the disease without compromising their subsequent serological diagnosis.
Recombinant technology: innovation in prevention
Recombinant vaccines are part of a new strategy and have been designed to ensure a targeted and effective immune response with a high level of safety.
Discover how protein Q, the active substance in the LetiFend® vaccine, was developed
Innovation against canine Leishmaniasis
- LetiFend®, a product obtained through recombinant DNA technology, the active substance of which is Protein Q.
- Protein Q, the active substance in LetiFend®, is a protein obtained by a combination of 5 highly antigenic fragments, fused and cloned in E. coli, from 4 Leishmania infantum proteins.
More information
Bibliography
- Letifend®: EPAR – Product Information (internet). European Medicines Agency. Available in: http://www.ema.europea.eu/en/medicines/veterinary/EPAR/letifend.
- Soto M, Requena JM, Quijada L, Angel SO, Gomez LC, Guzman F, Patarroyo ME, Alonso C. During active viscerocutaneous leishmaniasis the anti-P2 humoral response is specifically triggered by the parasite P proteins. Clin Exp Immunol. 1995 May;100(2):246-52. doi: 10.1111/j.1365-2249.1995.tb03661.x. PMID: 7743663; PMCID: PMC1534337.
- Soto M, Requena JM, Quijada L, García M, Guzman F, Patarroyo ME, Alonso C. Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis. Immunol Lett. 1995 Dec;48(3):209-14. doi: 10.1016/0165-2478(95)02473-5. PMID: 8867853.
- Soto M, Requena JM, Quijada L, Guzman F, Patarroyo ME, Alonso C. Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis. Immunol Lett. 1995 Nov;48(1):23-8. doi: 10.1016/0165-2478(95)02436-0. PMID: 8847086.
- Soto M, Requena JM, Quijada L, Alonso C. Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis. J Clin Microbiol. 1998;36(1):58-63. doi:10.1128/JCM.36.1.58-63.1998
- Nieto CG, García-Alonso M, Requena JM, Mirón C, Soto M, Alonso C, Navarrete I. Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis. Vet Immunol Immunopathol. 1999 Feb 1;67(2):117-30. doi: 10.1016/s0165-2427(98)00213-x. PMID: 10077418.
- Iniesta V, Fernández-Cotrina J, Solano-Gallego L, Monroy I, Gomez-Luque A, Muñoz-Madrid R, et al. VAccination with Letifend®, a novel canine leishmaniosis vaccine, does not interfere with serological diagnostic test. X Southern European Veterinary Conference / 51º Congreso Nacional AVEPA, 2016. Granada (Spain).
- Miró G, Acosta C, Marqués de Brito N, Ribas del Río F, Tabar MD, Iniesta V et al. Estudio piloto multicéntrico post-autorización sobre la seguridad de la vacuna LetiFend en perros en España. XXXIV Congreso Anual de AMVAC 2017. Madrid (Spain).
- Fernández Cotrina J, Iniesta V, Monroy I, Baz V, Hugnet C, Marañon F, Fabra M, Gómez-Nieto LC, Alonso C. A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend® against canine leishmaniosis. Vaccine. 2018 Apr 5;36(15):1972-1982. doi: 10.1016/j.vaccine.2018.02.111. Epub 2018 Mar 7. PMID: 29525281.
- Parody N, Cacheiro-Llaguno C, Osuna C, Renshaw-Calderón A, Alonso C, Carnés J. Circulating immune complexes levels correlate with the progression of canine leishmaniosis in naturally infected dogs. Vet Parasitol. 2019 Oct;274:108921. doi: 10.1016/j.vetpar.2019.108921. Epub 2019 Sep 8. PMID: 31536867.
- Cacheiro-Llaguno C, Parody N, Renshaw-Calderón A, Osuna C, Alonso C, Carnés J. Vaccination with LetiFend® reduces circulating immune complexes in dogs experimentally infected with L. infantum. Vaccine. 2020 Jan 22;38(4):890-896. doi: 10.1016/j.vaccine.2019.10.078. Epub 2019 Nov 6. PMID: 31706810.
- Cacheiro-Llaguno C, Parody N, Escutia MR, Carnés J. Role of Circulating Immune Complexes in the Pathogenesis of Canine Leishmaniasis: New Players in Vaccine Development. Microorganisms. 2021 Mar 30;9(4):712. doi: 10.3390/microorganisms9040712. PMID: 33808383; PMCID: PMC8066116.